OXB (OXB), formerly Oxford BioMedica, enjoyed a steady first half after the contract medicines manufacturer reported a 9 per cent increase in revenues to £79.8mn, as new client wins and stronger ...

New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end ...

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the 'Most Innovative CDMO (Cell & Gene Therapy)' ...

Oxford Innotech Bhd managing director Ng Thean Gin. PETALING JAYA: Oxford Innotech Bhd (OXB) has accepted a second letter of award from the Singapore office of an Australia-based data centre (DC) and ...

PETALING JAYA: Oxford Innotech Bhd (OXB) has accepted a second letter of award from the Singapore office of an Australia-based data centre and computer room infrastructure specialist to supply ...

Even amid the industry's cell and gene therapy reckoning of the past few years, Bristol Myers Squibb's CAR-T division has continued to reach new heights. (cagkansayin/Getty Images) OXB, a U.K.-based ...

Live webcasts and recordings of presentations, where available, will be accessible under 'Results, Reports, Presentations & Webcasts' in the Investor Relations section of OXB's website at www.oxb.com.

Live webcasts and recordings of presentations, where available, will be accessible under 'Results, Reports, Presentations & Webcasts' in the Investor Relations section of OXB's website at www.oxb.com.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A large manufacturing facility ...

U.K. cell and gene therapy manufacturing pioneer OXB has bought a viral vector plant in Durham, N.C., from National Resilience for $4.5 million. (Getty/Chris Ryan) Less than two months after OXB ...